Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06225830 · ClinicalTrials.gov registry record · NA
Unlocking Movement Potential: Enhancing Parkinson's Disease Treatment With Robotic EksoSkeleton
A NA study of Parkinson Disease, sponsored by Albert Einstein Healthcare Network.
- Recruiting
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06225830: Recruiting NA study of Parkinson Disease, sponsored by Albert Einstein Healthcare Network.
NCT06225830 is a NA study of Parkinson Disease that is actively recruiting participants, run by Albert Einstein Healthcare Network. The registered enrollment target is 24 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06225830, a NA study of Parkinson Disease, is actively recruiting participants, sponsored by Albert Einstein Healthcare Network.
- RECRUITING
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to see how well therapy with the Eksobionic Exoskeleton (Esko) works for people with Parkinson's disease (PWPD). Esko is a robotic device that provides high repetition and intensity training. The investigators will examine its impact on walking, balance, and quality of life before, during and after an eight-week intervention program. The results will lay the groundwork for future trials, potentially leading to long-term improvements in mobility and quality of life for PWPD.
Primary Outcome
Our goal is to determine the number of steps per session that can be achieved and the rate of progression through various Ekso modes while applying a standardized treatment protocol during Ekso mediated treatment in PwPD. We establish a treatment protocol for use of the Ekso with PwPD, involving two 45-60-minute sessions per week for eight weeks. We hypothesize that under this protocol, participants will achieve \>300 steps per session by the 3rd session and will be able to progress through a se
Conditions Studied
Interventions
- DEVICE Eksobionics Eksoskeleton NR
Study Locations (1)
Pennsylvania
- Jefferson Moss-Magee Rehabilitation - Elkins Park - Elkins Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-06-04 |
| Est. Completion | 2026-06 |
| Phase | NA |
What NCT06225830 shows while recruiting
NCT06225830 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Eksobionics Eksoskeleton NR is the first listed.
NCT06225830 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06225830 about?
NCT06225830 is a clinical study titled "Unlocking Movement Potential: Enhancing Parkinson's Disease Treatment With Robotic EksoSkeleton". The goal of this study is to see how well therapy with the Eksobionic Exoskeleton (Esko) works for people with Parkinson's disease (PWPD). Esko is a robotic device that provides high repetition and intensity training. The investigators will examine its impact on walking, balance, and quality of life...
What is the current status of trial NCT06225830?
This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2024-06-04. Estimated completion is 2026-06.
What conditions does trial NCT06225830 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT06225830?
The interventions under investigation include: Eksobionics Eksoskeleton NR (DEVICE).
Who is sponsoring clinical trial NCT06225830?
This trial is sponsored by Albert Einstein Healthcare Network, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06225830 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06225830's enrollment target sits among peer trials
24 232nd of 297 higher than 61 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Neurophysiology of Reward Signaling in Parkinson's Disease
RECRUITING · NA
-
Balance Tele-Rehab in Parkinson's Disease Parkinson's Disease
RECRUITING · NA
-
Rock Steady Boxing: A Community Based In Person Class
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI